icon-folder.gif   Conference Reports for NaTaP  
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside
Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Hua Tan, Kenneth Shaw, Andreas Jekle, Jerome Deval, Zhinan Jin, Amy Fung, Yuen Tam, Lawrence M. Blatt, Sushmita M. Chanda, Guangyi Wang, Natalia Dyatkina, Marija Prhavc, Caroline Williams, Vlad Serebryany, Qingling Zhang, Julian A. Symons, Leonid Beigelman and David B. Smith*
Alios BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, CA, USA.
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
AASLD/2014: Analysis of AL-335, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the HCV Subgenomic Replicon
Alios/J&J HCV Nucleotides Preclinical Data at AASLD / Alios BioPharma to Present Preclinical Data on its Anti-HCV Nucleotides AL-335 and AL-516......http://www.natap.org/2014/AASLD/AASLD_14.htm
.........Johnson & Johnson Announces Agreement To Acquire Alios BioPharma's HCV Nukes.......http://www.natap.org/2014/HCV/101514_01.htm